{"title":"比较超低剂量（炔雌醇 20 μg 或 15 μg）与低剂量（炔雌醇 30 μg）荷尔蒙药片对非肥胖多囊卵巢综合征女性血脂不协调影响的随机对照试验","authors":"Subhankar Dasgupta, Joyeeta Mondal, Barnali Goswami, Jija Dasgupta","doi":"10.1097/ogx.0000000000001264","DOIUrl":null,"url":null,"abstract":"(Abstracted from Obstet Gynecol Sci 2023;66:572–583\n Polycystic ovary syndrome (PCOS) is frequently treated using low-dose hormonal pills with ethinylestradiol (EE) 35 μg combined with progestins for cycle control. Use of these combined oral contraceptives has been associated with metabolic syndrome, dyslipidemia, and a risk of cardiovascular events for women with metabolic disorders.","PeriodicalId":509854,"journal":{"name":"Obstetrical & Gynecological Survey","volume":"133 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Randomized Control Trial to Compare Effects of Ultra-Low Dose (Ethinylestradiol 20 μg or 15 μg) With Low Dose (Ethinylestradiol 30 μg) Hormonal Pills on Lipid Discordance in Non-Obese PCOS Women\",\"authors\":\"Subhankar Dasgupta, Joyeeta Mondal, Barnali Goswami, Jija Dasgupta\",\"doi\":\"10.1097/ogx.0000000000001264\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"(Abstracted from Obstet Gynecol Sci 2023;66:572–583\\n Polycystic ovary syndrome (PCOS) is frequently treated using low-dose hormonal pills with ethinylestradiol (EE) 35 μg combined with progestins for cycle control. Use of these combined oral contraceptives has been associated with metabolic syndrome, dyslipidemia, and a risk of cardiovascular events for women with metabolic disorders.\",\"PeriodicalId\":509854,\"journal\":{\"name\":\"Obstetrical & Gynecological Survey\",\"volume\":\"133 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obstetrical & Gynecological Survey\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/ogx.0000000000001264\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetrical & Gynecological Survey","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/ogx.0000000000001264","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Randomized Control Trial to Compare Effects of Ultra-Low Dose (Ethinylestradiol 20 μg or 15 μg) With Low Dose (Ethinylestradiol 30 μg) Hormonal Pills on Lipid Discordance in Non-Obese PCOS Women
(Abstracted from Obstet Gynecol Sci 2023;66:572–583
Polycystic ovary syndrome (PCOS) is frequently treated using low-dose hormonal pills with ethinylestradiol (EE) 35 μg combined with progestins for cycle control. Use of these combined oral contraceptives has been associated with metabolic syndrome, dyslipidemia, and a risk of cardiovascular events for women with metabolic disorders.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
